Rules-Based Medicine Newswire (Page 5)

Rules-Based Medicine Newswire (Page 5)

Comprehensive Real-Time News Feed for Rules-Based Medicine. (Page 5)

Results 81 - 100 of 1,004 in Rules-Based Medicine

  1. Myriad Genetics, Inc. (MYGN) Rating Reiterated by Jefferies Group LLCRead the original story w/Photo

    May 3, 2017 | Daily Political

    's stock had its "hold" rating reaffirmed by equities research analysts at Jefferies Group LLC in a note issued to investors on Wednesday. They presently have a $21.00 price target on the stock, up from their previous price target of $18.00.

    Comment?

  2. Myriad Genetics, Inc. (MYGN) Updates Q4 Earnings GuidanceRead the original story w/Photo

    May 3, 2017 | Daily Political

    Myriad Genetics, Inc. updated its fourth quarter earnings guidance on Tuesday. The company provided earnings per share guidance of $0.26-0.28 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.26.

    Comment?

  3. Myriad Genetics, Inc. (MYGN) Given Consensus Recommendation of "Hold" by AnalystsRead the original story w/Photo

    May 3, 2017 | AmericanBankingNews.com

    Myriad Genetics, Inc. has been given an average rating of "Hold" by the sixteen ratings firms that are covering the stock. Three equities research analysts have rated the stock with a sell rating, nine have given a hold rating and two have given a buy rating to the company.

    Comment?

  4. Myriad Genetics Reports Fiscal Third-Quarter 2017 Financial ResultsRead the original story

    May 2, 2017 | BioSpace

    SALT LAKE CITY, May 02, 2017 -- Myriad Genetics, Inc. , a global leader in molecular diagnostics and personalized medicine, today announced financial results for its fiscal third-quarter 2017, provided an update on recent business highlights and updated its fiscal year 2017 financial guidance. "We were very encouraged to see sequential growth in hereditary cancer testing volumes for the second consecutive quarter," said Mark C. Capone, president and CEO, Myriad Genetics.

    Comment?

  5. Myriad Genetics, Inc. (MYGN) Issues Q4 Earnings GuidanceRead the original story w/Photo

    May 2, 2017 | IntersportsWire

    Myriad Genetics, Inc. issued an update on its fourth quarter earnings guidance on Tuesday morning. The company provided EPS guidance of $0.26-0.28 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.26.

    Comment?

  6. Myriad Genetics (MYGN) Receives News Impact Score of 0.39Read the original story w/Photo

    Apr 29, 2017 | AmericanBankingNews.com

    Media coverage about Myriad Genetics has trended positive recently, AlphaOne Sentiment reports. The research group, a subsidiary of Accern, identifies positive and negative press coverage by reviewing more than twenty million blog and news sources.

    Comment?

  7. Myriad Genetics, Inc. (MYGN) Sees Large Decrease in Short InterestRead the original story w/Photo

    Apr 27, 2017 | IntersportsWire

    Myriad Genetics, Inc. was the target of a significant drop in short interest in March. As of March 31st, there was short interest totalling 24,260,475 shares, a drop of 5.7% from the March 15th total of 25,737,189 shares.

    Comment?

  8. Myriad Genetics And Clovis Oncology Sign Agreement For Use Of...Read the original story

    Apr 26, 2017 | BioSpace

    Myriad Genetics , Inc. and Clovis Oncology, Inc. today announced a companion diagnostic collaboration to support a post-marketing regulatory commitment related to Clovis' PARP inhibitor, Rubraca. Financial terms of the deal were not disclosed.

    Comment?

  9. Technical Roundup on Research Services Stocks -- Myriad Genetics,...Read the original story w/Photo

    Apr 27, 2017 | PR Newswire

    The Research Services space comprises companies that offer services such as aiding in marketing activities, and studying and analyzing the market as per client needs and specifications. Pre-market, Stock-Callers.com observes the recent performances of these four stocks: Myriad Genetics Inc. , QIAGEN N.V. , INC Research Holdings Inc. , and Bioanalytical Systems Inc. .

    Comment?

  10. Myriad Genetics, Inc. (MYGN) Rating Reiterated by Cowen and CompanyRead the original story w/Photo

    Apr 26, 2017 | The Breeze

    The firm currently has a $19.00 target price on the stock. A number of other research firms also recently weighed in on MYGN.

    Comment?

  11. Myriad Genetics, Inc. (MYGN) Sees Large Decline in Short InterestRead the original story w/Photo

    Apr 21, 2017 | Daily Political

    Myriad Genetics, Inc. was the target of a large drop in short interest in March. As of March 31st, there was short interest totalling 24,260,475 shares, a drop of 5.7% from the March 15th total of 25,737,189 shares.

    Comment?

  12. Parametrica Management Ltd Invests $236,000 in Myriad Genetics, Inc.Read the original story w/Photo

    Apr 19, 2017 | The Breeze

    Parametrica Management Ltd purchased a new stake in Myriad Genetics, Inc. during the first quarter, according to its most recent disclosure with the SEC. The fund purchased 12,275 shares of the company's stock, valued at approximately $236,000.

    Comment?

  13. Myriad Genetics To Announce Fiscal Third-Quarter 2017 Financial Results On May 2, 2017Read the original story

    Apr 18, 2017 | BioSpace

    Myriad Genetics, Inc. today announced that it will hold its fiscal third-quarter 2017 sales and earnings conference call with investors and analysts at 4:30 p.m. ET on Tuesday, May 2, 2017. During the call, Mark C. Capone, president and CEO and Bryan Riggsbee, CFO, will provide an overview of Myriad's financial performance for the fiscal third-quarter and provide a business update.

    Comment?

  14. Opus Point Partners Management LLC Buys Shares of 13,907 Myriad Genetics, Inc.Read the original story w/Photo

    Apr 19, 2017 | IntersportsWire

    Opus Point Partners Management LLC bought a new stake in shares of Myriad Genetics, Inc. during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm bought 13,907 shares of the company's stock, valued at approximately $232,000.

    Comment?

  15. Myriad Genetics, Inc. (MYGN) Receives "Hold" Rating from Jefferies Group LLCRead the original story w/Photo

    Apr 18, 2017 | IntersportsWire

    Other analysts have also issued reports about the stock. Piper Jaffray Companies set a $21.00 price objective on shares of Myriad Genetics and gave the company a hold rating in a report on Sunday, December 25th.

    Comment?

  16. Myriad to Announce Fiscal Third-Quarter 2017 Financial Results on May 2, 2017Read the original story

    Apr 18, 2017 | World News Report

    Myriad Genetics, Inc. today announced that it will hold its fiscal third-quarter 2017 sales and earnings conference call with investors and analysts at 4:30 p.m. ET on Tuesday, May 2, 2017.  During the call, Mark C. Capone, president and CEO and Bryan Riggsbee, CFO, will provide an overview of Myriad's financial performance for the fiscal third-quarter and provide a business update. To listen to the call, interested parties in the United States may dial 888-225-2744 or +1 303-223-2690 for international callers.  All callers will be asked to reference reservation number 21849837.

    Comment?

  17. Myriad Genetics, Inc. (MYGN) Earns "Market Perform" Rating from Cowen and CompanyRead the original story w/Photo

    Apr 18, 2017 | IntersportsWire

    A number of other research firms also recently issued reports on MYGN. Ladenburg Thalmann Financial Services upgraded Myriad Genetics from a sell rating to a neutral rating in a report on Wednesday, February 8th.

    Comment?

  18. Comerica Bank Acquires 2,348 Shares of Myriad Genetics, Inc.Read the original story w/Photo

    Apr 17, 2017 | IntersportsWire

    Comerica Bank boosted its position in Myriad Genetics, Inc. by 4.8% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission . The institutional investor owned 51,750 shares of the company's stock after buying an additional 2,348 shares during the period.

    Comment?

  19. Study Finds Wide Gap In Quality Of BRCA1/2 Variant Classification...Read the original story

    Apr 16, 2017 | BioSpace

    Myriad Genetics , Inc. , a leader in molecular diagnostics and personalized medicine, today announced that new data comparing BRCA1 and BRCA2 variant classifications between Myriad Genetics and a commonly used public genetic database was published in the journal The Oncologist .1 A key finding was that the public database provided discrepant variant classifications more than 26 percent of the time, which can introduce uncertainty and diminish patient care. The study, done in collaboration with William Gradishar, M.D., from the Feinberg School of Medicine at Northwestern University, evaluated 4,250 BRCA1 and BRCA2 variants.

    Comment?

  20. Myriad Genetics (MYGN) Getting Somewhat Positive Press Coverage, Study FindsRead the original story w/Photo

    Apr 16, 2017 | AmericanBankingNews.com

    News coverage about Myriad Genetics has trended somewhat positive recently, according to Alpha One Sentiment. Alpha One, a unit of Accern, rates the sentiment of media coverage by reviewing more than 20 million news and blog sources in real-time.

    Comment?